SCHEMBL6467255

SCHEMBL6467255

Cc1cc(NC2CCC(NC(=O)COc3ccc(Cl)c(Cl)c3)CC2)nc2ccccc12

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.51
LMNA P02545 4/20 0.51
KDM4E B2RXH2 1/20 0.51
HPGD P15428 1/20 0.51
HTT P42858 1/20 0.51
RAB9A P51151 1/20 0.51
MCHR1 Q99705 3/20 0.48
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
ATF4 P18848 2/20 0.46
RXFP1 Q9HBX9 2/20 0.46
USP2 O75604 1/20 0.45
MAPK1 P28482 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
ADRA2A P08913 1/20 0.45
ALDH1A1 P00352 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6462974 1.00 SMN1; SMN2 (0.51) SMN1; SMN2LMNAKDM4EHPGDHTT
Hydrochloric Acid SCHEMBL6458851 0.99 SMN1; SMN2 (0.50) SMN1; SMN2LMNAKDM4EHPGDHTT
Hydrochloric Acid SCHEMBL6458860 0.99 SMN1; SMN2 (0.50) SMN1; SMN2LMNAKDM4EHPGDHTT
SCHEMBL6467219 0.92 LMNA (0.48) SMN1; SMN2LMNAKDM4EHPGDHTT
SCHEMBL6467223 0.92 LMNA (0.48) SMN1; SMN2LMNAKDM4EHPGDHTT
Hydrochloric Acid SCHEMBL6456405 0.91 MCHR1 (0.48) SMN1; SMN2LMNAKDM4EHPGDHTT
Hydrochloric Acid SCHEMBL6456398 0.91 MCHR1 (0.48) SMN1; SMN2LMNAKDM4EHPGDHTT
SCHEMBL6463881 0.91 ATF4 (0.58) SMN1; SMN2LMNAKDM4EHPGDHTT
SCHEMBL6463886 0.91 ATF4 (0.58) SMN1; SMN2LMNAKDM4EHPGDHTT
SCHEMBL6464711 0.89 MCHR1 (0.52) SMN1; SMN2LMNAKDM4EHPGDHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050197350-A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof TAISHO PHARMACEUTICAL CO., LTD. 2005-09-08 US claimed
WO-2004087669-A1 NOVEL QUINOLINE, TETRAHYDROQUINAZOLINE, AND PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF TAISHO PHARMACEUTICAL CO. LTD. (JP) 2004-10-14 WO claimed
EP-1464335-A2 Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist Taisho Pharmaceutical Co. Ltd. (JP) 2004-10-06 EP claimed
US-20050197350-A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof TAISHO PHARMACEUTICAL CO., LTD. 2005-09-08 US disclosed
WO-2004087669-A1 NOVEL QUINOLINE, TETRAHYDROQUINAZOLINE, AND PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF TAISHO PHARMACEUTICAL CO. LTD. (JP) 2004-10-14 WO disclosed
EP-1464335-A2 Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist Taisho Pharmaceutical Co. Ltd. (JP) 2004-10-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197350-A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof HCRTR2, MCHR1, MCHR2 SMN1; SMN2 1477/4885LMNA 3391/4885KDM4E 1190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.